What is Ribrecabtagene Autoleucel (DRL-1801)?

Ribrecabtagene Autoleucel (DRL-1801)

Overview:

• Ribrecabtagene Autoleucel (DRL-1801) is a novel Chimeric Antigen Receptor T-cell (CAR-T) therapy under development. It represents a cutting-edge approach in personalized cancer immunotherapy.
• Developed by Dr. Reddy’s Laboratories in collaboration with global research entities.

Mechanism of Action:

• This therapy uses genetically engineered T-cells designed to target and destroy cancer cells.
• DRL-1801 is engineered to recognize specific proteins on cancer cells, such as CD19, commonly expressed in blood cancers like leukemia and lymphoma.

Key Applications:

• Targeted for relapsed or refractory B-cell malignancies such as:
  • Acute Lymphoblastic Leukemia (ALL).
  • Non-Hodgkin’s Lymphoma (NHL).
• Particularly beneficial for patients who have failed conventional treatments.

Development Status:

• Currently undergoing clinical trials to assess its safety and efficacy.
• India has been advancing CAR-T technology domestically to make it more affordable compared to international counterparts.